At Reprogram Biosciences, cell reprogramming is at the center of a new way of thinking about therapeutics. Below, Rustam Esanov (CEO) and Eziz Kuliyev (COO) from Reprogram Bio shares—in their own words—how the team is approaching this shift, where they are focusing first, and how partnering with Helix has helped accelerate their work.​ Reprogram’s Mission and Current Focus “To start, could you give a quick overview of Reprogram Biosciences and what your current main project

When Should You Use a Standard LNP Composition versus a Custom Lipid/Polymer Formulation?

Most mRNA programs begin the same way. A coding sequence or gene of interest is selected. A codon optimization tool is run. The GC content looks acceptable. The sequence is ordered. Then expression is lower than expected, stability is inconsistent, innate immune activation appears, and manufacturing yields are unpredictable. The assumption was simple: optimize codon frequency and translation will improve. Reality is more complex. Codon optimization is only one variable in a m

In recent conversations with clients, there's been a surge of interest around a rather intriguing subject in the biotech world: lipid nanoparticles (LNPs) and, specifically, the state-of-the-art mixing techniques used in their production. Clients do not know the difference between the turbulent mixing approach and that of microfluidics - they often come to us to enlighten them and explain which one is better! Over the years, our team has witnessed the evolution of numerous m

Nine elephant calves at the Houston, Fort Worth, Rosamond Gifford, and Cincinnati zoos, received a groundbreaking EEHV mRNA-LNP vaccine developed through the efforts between Baylor College of Medicine, Helix Biotech, Avanti Polar Lipids/Croda and partner zoos.